SystImmune Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SystImmune's estimated annual revenue is currently $8.5M per year.(i)
  • SystImmune's estimated revenue per employee is $103,963

Employee Data

  • SystImmune has 82 Employees.(i)
  • SystImmune grew their employee count by 52% last year.

SystImmune's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Clinical DevelopmentReveal Email/Phone
3
VP, Immuno-OncologyReveal Email/Phone
4
VP, Finance & Business OperationsReveal Email/Phone
5
SVP, Finance & Business OperationsReveal Email/Phone
6
Associate Director Medical WritingReveal Email/Phone
7
Sr Director Clinical OperationsReveal Email/Phone
8
Senior Project ManagerReveal Email/Phone
9
Senior ScientistReveal Email/Phone
10
Principal Scientist IIReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M50%N/AN/A
#2
$0.9M50%N/AN/A
#3
$5.1M3011%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M415%$10.1MN/A
#7
$1.1M1183%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M8100%N/AN/A
Add Company

What Is SystImmune?

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

keywords:N/A

N/A

Total Funding

82

Number of Employees

$8.5M

Revenue (est)

52%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.9M82-5%N/A
#2
$24.9M8336%N/A
#3
$9.6M8414%N/A
#4
$17M8427%N/A
#5
$5.7M8767%N/A